We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ADMA Biologics, Inc. is one of the best ...

ADMA Biologics ADMA and Takeda TAK are prominent players in the plasma-derived immunoglobulin space. ADMA focuses on ...

ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ADMA BIOLOGICS, INC. (ADMA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

The MarketWatch News Department was not involved in the creation of this content. Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business ...

ADMA announced the FDA's approval of its yield enhancement process. The company's yield enhancement process has demonstrated the ability to increase production yields by approximately 20%.

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, ...

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best low priced biotech stocks to invest in. Mizuho cut the price target on ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income (1) of ...

ADMA Biologics’ ADMA shares have plunged 42.5% year to date against the industry’s growth of 1.6%.  The stock has also ...

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and ...